| Literature DB >> 35445085 |
Hoorak Poorzand1, Fatemeh Hamidi2,3, Fereshte Sheybani4, Fereshteh Ghaderi2, Afsoon Fazlinezhad2, Hedieh Alimi1, Leila Bigdelu2, Saeede Khosravi Bizhaem3.
Abstract
Purpose: Infective endocarditis (IE) remains a disease with high morbidity and mortality. The aim of this study was to determine the clinical characteristics and echocardiographic features of patients with IE.Entities:
Keywords: congenital heart disease; echocardiography; follow-up care; infective endocarditis; mortality rate
Year: 2022 PMID: 35445085 PMCID: PMC9014855 DOI: 10.3389/fcvm.2022.789624
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Enrolment protocol of patients with definite or possible infective endocarditis.
Patient characteristics and the underlying condition.
|
| |||
|---|---|---|---|
| Age, (<65 years) | 74 (90.3) | ||
| Gender (male) | 52 (63.4) | ||
| Comorbidities | |||
| Chronic obstructive pulmonary disease (COPD/asthma) | 17 (20.7%) | ||
| Hypertension | 14 (17%) | ||
| End stage renal disease (ESRD) | 13 (15.8%) | ||
| Diabetes mellitus | 13 (15.8) | ||
| History of CAD | 11 (13.4) | ||
| Immunocompromised state | 8 (9.7) | ||
| Heart failure | 7 (8.5) | ||
| Cancer | 3 (3.6) | ||
| Pregnancy | 2 (2.4) | ||
| Duke criteria | |||
| 2 major criteria | 37 (45.1) | ||
| 1 major criteria | 40 (48.7) | ||
| 3 minor criteria (with and without major criteria) | 27 (32.9) | ||
| Predisposing condition | |||
| Congenital heart disease | 23 (28) | ||
| Bicuspid aortic valve | 12 (14.6) | ||
| VSD | 9 (11) | ||
| TOF | 2 (2.4) | ||
| Central venous catheter | 16 (19.5) | ||
| IVDU | 12 (14.6) | ||
| Prosthetic valve | 8 (9.7) | ||
| Bioprosthetic valve | 1 (1.2) | ||
| Mechanical valve | 7 (8.5) | ||
| Degenerative valve disease | 6 (7.3) | ||
| Rheumatic heart disease | 3 (3.6) | ||
| Device implantation | 4 (4.9) | ||
| Previous IE | 1 (1.2) | ||
| Prior antibiotic therapy within the last 2 weeks | 28 (34.1) | ||
| Recent dental procedure | 2 (2.4) | ||
| New York Heart Association (NYHA) classification | |||
| I | 12 (14) | ||
| II | 24 (29) | ||
| III | 28 (34) | ||
| IV | 19 (23) | ||
Clinical characteristics, laboratory features, with systemic and cardiac complications on admission.
|
| |||
|---|---|---|---|
| Symptoms | Malaise | 71 (86.5) | |
| Fever | 71 (86.5) | ||
| Loss of appetite | 65 (79.25) | ||
| Shortness of breath | 62 (75.6) | ||
| Cough | 31 (37.8) | ||
| Sweating | 31 (37.8) | ||
| Dizziness | 25 (30.4) | ||
| Muscle pain | 25 (30.4) | ||
| Signs | Cardiac murmur | 71 (86.5) | |
| Congestive heart failure (NYHA IV) | 19 (23.1) | ||
| Peripheral stigmata | Janeway lesions | 12 (14.6) | |
| Osler's node | 2 (2.4) | ||
| Roth spots | 1 (1.2) | ||
| Clubbing | 1 (1.2) | ||
| Cardiac and systemic complications | Major embolic events | 31 (37.8) | |
| Limb ischemia | 1 (1.2) | ||
| Cerebrovascular complications | TIA | 1 (1.2) | |
| Ischemic stroke | 14 (17.0) | ||
| Hemorrhagic stroke | 2 (2.4) | ||
| Pulmonary emboli | 12 (14.6) | ||
| Septic shock | 8 (9.7) | ||
| Acute pulmonary edema | 7 (8.5) | ||
| Cardiogenic shock | 4 (4.9) | ||
| Coronary artery involvement (Left circumflex and right coronary artery) | 2 (2.4) | ||
| Causative pathogen | Positive result | 36 (43.9) | |
|
| 7 (19.4) | ||
| MERSA (methicillin-resistance | 3(8.3) | ||
| Viridans streptococci | 3 (8.3) | ||
| Enterococcal species | 3 (8.3) | ||
| Pseudomonas species | 3 (8.3) | ||
| HACECK | 2 (2.4) | ||
| Candida | 2 (2.4) | ||
| Acinetobacter | 1 (1.2) | ||
| Brucellosis (Positive tissue sample culture) | 1 (1.2) | ||
| Others (staph coagulase positive, staph epidermis, strep group D, strep agalactiae, kelebsiella pneumonia, …) | 14 (17.07) | ||
| BCNIE | 46 (56.1) | ||
| Other laboratory findings | Parameter | Median | IQR (Q3, Q1) |
| Hemoglobin (mg/dl) | 9.2 | 2.9 (11, 8.1) | |
| WBC (×103) | 8.9 | 7.4 (13.2, 6.8) | |
| Platelets (×103) | 166 | 196.5 | |
| Creatinine, mg/dl | 1.1 | 1.3 (2.2, 1.9) | |
| CRP | 90 | 44.5 | |
| ESR | 69 | 53.5 | |
Median and interquartile range were used. BCNE, Blood culture negative endocarditis.
Echocardiographic characteristics.
|
| ||||
|---|---|---|---|---|
| Vegetation location | Single valve involvement | Aortic | Native | 13 (15.9) |
| Biologic | 1 (1.2) | |||
| MV | Native | 16 (19.5) | ||
| Mechanical | 4 (4.9) | |||
| TV | Native | 15 (18.3) | ||
| Multivalve involvement | Ao V + MV | Native | 9 (10.1) | |
| Ao V + MV | Mechanical | 3 (3.6) | ||
| MV+ TV | Native | 2 (2.4) | ||
| Ao V (native) and IVS (VSD case) | 3 (3.6) | |||
| TV (native) and IVS (VSD case) | 2 (2.4) | |||
| MV (native) and SVC | 4 (4.9) | |||
| Isolated SVC | 4 (4.9) | |||
| Isolated IVS (VSD peri-membranous) | 3 (3.6) | |||
| LTGA(VSD) | 1 (1.2) | |||
| Pulmonary conduit (TOF) | 1 (1.2) | |||
| RV wall (TOF) | 1 (1.2) | |||
| Total | 82 (100) | |||
| TV | Hx of IVDU | 11 (57.8) | ||
| No Hx of IVDU | 8 (42.2) | |||
| Complicated IE | Ao V | 52 (63.2) | ||
| MV | 52 (63.1) | |||
| TV | 31 (37.8) | |||
AoV, Aortic valve; MV, Mitral valve; TV, Tricuspid valve.
Frequency of systemic and cardiac complications during hospital admission.
|
| |
|---|---|
| Adverse drug reactions related to antibiotic therapy | 27 (32.9) |
| Acute renal failure | 19 (23.2) |
| Congestive heart failure | 14 (17.07) |
| Glomerulonephritis | 8 (9.8) |
| Neurologic complications | 8 (9.8) |
| Stroke | 3 (3.7) |
| Cerebral mycotic aneurysm | 3 (3.7) |
| Intracerebral hemorrhage | 2 (2.4) |
| Septic shock | 7 (8.5) |
| Splenic abscess | 1 (1.2) |
| Coronary artery embolism | 1 (1.2) |
| New abscess formation in aortic valve | 1 (1.2) |
Univariate Cox proportional hazard model.
|
|
|
|
|---|---|---|
| Renal failure (ESRD) | 1.425 (0.620–3.276) | 0.404 |
| Immunosuppressive treatment | 1.502 (0.526–4.292) | 0.447 |
| Septic shock | 13.608 (6.009–30.817) | <0.001 |
| Heart failure | 2.210 (1.022–4.779) | 0.044 |
| Not performed surgery | 1.571 (0.756–3.262) | 0.226 |
| Negative blood culture infective endocarditis (NBCIE) | 0.801 (0.401–1.603) | 0.531 |
Figure 2Kaplan-Meier curve showing the probability of mortality respect to the time of admission.